May 1, 2018 06:25 AM EDT
R&D
Pharma

Gilead joins the line­up of big bio­phar­ma part­ners to al­ly with Ver­i­ly — this time fo­cused on im­munol­o­gy

John Carroll

Editor & Founder

Ver­i­ly Life Sci­ences will put its im­munol­o­gy plat­form Im­munoscape to work for Gilead, prob­ing the im­mune cells of pa­tients suf­fer­ing from rheuma­toid arthri­tis, in­flam­ma­to­ry bow­el …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times